Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
PLAQUENIL |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
DMARD (aminoquinoline). |
| Generic Name |
|
Hydroxychloroquine sulfate 200mg; tabs. |
| Indications |
|
Refractory rheumatoid arthritis or lupus erythematosus. |
| Children |
|
Not recommended. |
| Adults |
|
Rheumatoid arthritis: initially 400–600mg daily with food or milk. Lupus: initially 400mg 1–2 times daily. Maintenance for both: 200–400mg daily. |
| Contraindications |
|
Long-term use in children. Retinal or visual field changes. |
| Precautions |
|
Be fully familiar with this product's toxicity before use. Psoriasis. Porphyria. Hepatic dysfunction. Alcoholism. G6PD deficiency. Monitor ocular function, reflexes, and blood in chronic use. Discontinue if blood dyscrasias, visual symptoms or muscular weakness occur or if ineffective after 6 months in rheumatoid arthritis. Pregnancy: not recommended. Nursing mothers. |
| Interactions |
|
Avoid other hepatotoxic or dermatotoxic drugs. |
| Adverse Reactions |
|
Irreversible retinopathy, blurred vision, corneal edema or deposits, visual field defects, irritability, neuromuscular dysfunction, hair bleaching, alopecia, pruritus, skin pigmentation, rash, blood dyscrasias, anorexia, nausea, weight loss. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
